Schering-Plough Canada announces a $30.7 million expansion of its production plant in Pointe-Claire
Advertisement
Schering-Plough Canada announced it will invest over $30 million to expand its Pointe-Claire production plant. The expansion of the plant, which currently employs 330 people, is expected to create additional employment opportunities. Also, during construction, 150 workers will be employed full-time. Additionally, many of the materials needed for the expansion have been bought from local suppliers. The production expansion will increase annual production to 35 million units.
"We are very pleased to have partnered with the Government of Québec on this important project," said Carlos Dourado, President and General Manager of Schering-Plough Canada. "Investissement Québec provided a $3 million grant and this was very important in Schering-Plough Corporation choosing Quebec for this facility, among many other possible locations around the world."
Most read news
Organizations
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New Mechanism for Cardiac Arrhythmia discovered

Falling Walls Foundation awarded the final three titles for the Scientific Breakthrough of the Year 2023 - Categories: Science Engagement, Science Start-Ups and Emerging Talents
Researchers rapidly turn bacteria into biotech factories
Biovitrum has Successfully Completed the First Phase I Trial of its 5-HT6 Receptor Antagonist (BVT.74316)
Baxter and Cerus Halt Red Blood Cell Clinical Trials for Investigational Pathogen Inactivation System
Cornell receives almost $2 million from New York state for stem cell research
Actelion and Roche enter into autoimmune disorder collaboration
